1-[2-(2,6-dimethylphenoxy)ethyl]-2-piperidin-1-ylmethyl-1H-benzimidazole | 931337-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[2-(2,6-dimethylphenoxy)ethyl]-2-piperidin-1-ylmethyl-1H-benzimidazole
• 英文别名: 1-[2-(2,6-dimethylphenoxy)ethyl]-2-(piperidin-1-ylmethyl)benzimidazole
• CAS: 931337-74-5
• 化学式: C₂₃H₂₉N₃O
• mdl: MFCD12961969
• 分子量: 363.503
• InChiKey: BDCITPDMWCPVIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯甲基苯并咪唑 在 potassium carbonate 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.75h， 生成 1-[2-(2,6-dimethylphenoxy)ethyl]-2-piperidin-1-ylmethyl-1H-benzimidazole
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
  [FR] DÉRIVÉS BENZIMIDAZOLE EN TANT QUE BLOQUEURS SÉLECTIFS DU COURANT DE SODIUM PERSISTANT

  摘要：

  本发明涉及治疗由持续性钠通道升高介导的疾病或症状的方法，例如眼部疾病、疼痛、多发性硬化和癫痫症，利用化合物I的方法或其药学上可接受的盐或包含该化合物的药物组合物，其中化合物I中的变量R、R1、R2、R3、R4、R5、m和n如本文所定义。

  公开号：

  WO2013101926A1

文献信息

• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
  申请人：Allergan, Inc.

  公开号：US20130172342A1

  公开（公告）日：2013-07-04

  The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R 1 , R 2 , R 3 , R 4 , R 5 , m, and n in Formula I are as defined herein.

  本发明涉及使用I式化合物或其药学上可接受的盐或包含该化合物的药物组合物来治疗由持续性钠通道升高引起的疾病或症状，例如眼部疾病、疼痛、多发性硬化和癫痫等。其中，I式中的变量R、R1、R2、R3、R4、R5、m和n的定义如本文所述。
• Compounds for the treatment of cancer and inflammatory disease
  申请人：SHY Therapeutics LLC

  公开号：US10221191B2

  公开（公告）日：2019-03-05

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供的化合物可抑制 MAPK 磷酸化，因此可用于治疗癌症和炎症性疾病的组合物和方法中。
• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：SHY Therapeutics LLC

  公开号：US10588894B2

  公开（公告）日：2020-03-17

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20190022074A1

  公开（公告）日：2019-01-24

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.